Merck & Co., Inc. (NYSE:MRK) Stock Position Trimmed by Chemung Canal Trust Co.


Share on StockTwits

Chemung Canal Trust Co. cut its position in Merck & Co., Inc. (NYSE:MRK) by 39.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 71,596 shares of the company’s stock after selling 46,827 shares during the quarter. Chemung Canal Trust Co.’s holdings in Merck & Co., Inc. were worth $5,857,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Pinnacle Bank lifted its position in Merck & Co., Inc. by 4.9% in the 4th quarter. Pinnacle Bank now owns 2,652 shares of the company’s stock valued at $217,000 after purchasing an additional 123 shares during the last quarter. Rosenberg Matthew Hamilton lifted its position in Merck & Co., Inc. by 8.9% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 1,562 shares of the company’s stock valued at $130,000 after purchasing an additional 127 shares during the last quarter. Madison Wealth Management raised its position in shares of Merck & Co., Inc. by 1.0% during the 3rd quarter. Madison Wealth Management now owns 12,832 shares of the company’s stock worth $1,064,000 after buying an additional 128 shares in the last quarter. Portland Global Advisors LLC raised its position in shares of Merck & Co., Inc. by 0.9% during the 3rd quarter. Portland Global Advisors LLC now owns 14,902 shares of the company’s stock worth $1,236,000 after buying an additional 133 shares in the last quarter. Finally, Stuart Chaussee & Associates Inc. raised its position in shares of Merck & Co., Inc. by 44.3% during the 3rd quarter. Stuart Chaussee & Associates Inc. now owns 433 shares of the company’s stock worth $36,000 after buying an additional 133 shares in the last quarter. Hedge funds and other institutional investors own 66.43% of the company’s stock.

Shares of NYSE:MRK traded down $0.75 during midday trading on Wednesday, hitting $82.34. 9,087,361 shares of the stock were exchanged, compared to its average volume of 10,221,937. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.00 and a current ratio of 1.30. Merck & Co., Inc. has a 52-week low of $65.25 and a 52-week high of $92.06. The business’s fifty day simple moving average is $81.41 and its two-hundred day simple moving average is $81.11. The company has a market capitalization of $208.32 billion, a PE ratio of 18.22, a P/E/G ratio of 1.96 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.44 by $0.30. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The business had revenue of $12.55 billion during the quarter, compared to analyst estimates of $12.21 billion. During the same period last year, the company earned $1.51 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 1.2% compared to the same quarter last year. As a group, equities analysts anticipate that Merck & Co., Inc. will post 5.9 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 8th. Investors of record on Tuesday, December 15th were issued a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a dividend yield of 3.16%. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.61. The ex-dividend date was Monday, December 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 50.10%.

MRK has been the topic of a number of recent analyst reports. Mizuho restated a “buy” rating and set a $100.00 price target on shares of Merck & Co., Inc. in a research report on Sunday, December 6th. Truist initiated coverage on shares of Merck & Co., Inc. in a research report on Friday, October 23rd. They set a “buy” rating and a $96.00 price target on the stock. SVB Leerink boosted their price target on shares of Merck & Co., Inc. from $100.00 to $103.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Sanford C. Bernstein restated an “outperform” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research report on Tuesday, November 10th. Finally, Berenberg Bank assumed coverage on shares of Merck & Co., Inc. in a report on Tuesday, September 29th. They issued a “hold” rating and a $88.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company. Merck & Co., Inc. has a consensus rating of “Buy” and a consensus price target of $95.36.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.

Further Reading: What is a Fiduciary?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.